Summary
Background
Methods
Results
Conclusions
Keywords
1. Introduction
EUA Authorized Serology Test Performance. U.S. food and drug administration website. https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-authorized-serology-test-performance. Revised June 92020. Accessed June 14, 2020.
- Long QX
- Liu BZ
- Deng HJ
- et al.
2. Methods
3. Case histories
3.1 Case 1
Case 1 | Case 2 | |||
---|---|---|---|---|
1st Test | 2nd Test | 1st Test | 2nd Test | |
DiaSorinLIAISON SARS-CoV-2 | RocheElecsysAnti-SARS-CoV-2 | Abbott Architect SARS-CoV-2 | Ortho-Clinical Diagnostics VITROS Anti-SARS-CoV-2 | |
Antibody | IgG | Pan-Ig | IgG | IgG |
Target | Spike | Nucleocapsid | Nucleocapsid | Spike |
Technology | High Throughput CMIA | High Throughput ECLIA | High Throughput CMIA | High Throughput CLIA |
Location | BioReference Labs | Northwell Labs | Quest Labs | Northwell Labs |
Estimate Interval After Symptom Onset | 7 weeks | 9 weeks | 6 weeks | 12 weeks |
Sensitivity* | 97.6% (40/41) | 100% (29/29) | 100% (88/88) | 90% (36/40) |
NPV at 5% Prevalence* | 99.9% | 100% | 100% | 99.5% |
Specificity* | 99.3 (1082/1090) | 99.8% (5262/5272) | 99.6% (1066/1070) | 100% (407/407) |
PPV at 5% Prevalence* | 88.0% | 96.5% | 92.9% | 100% |
3.2 Case 2
4. Discussion
- Long QX
- Liu BZ
- Deng HJ
- et al.
- Safavi F
- Nourbakhsh B
- Azimi AR
- Sormani MP
- Soresina A
- Moratto D
- Chiarini M
- et al.
Declaration of Competing Interests
Funding
References
- Humoral Responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.Arthritis Rheum. 2010 Jan; 62: 75-81https://doi.org/10.1002/art.25033
- COVID-19 and MS disease-modifying therapies.Neurol. Neuroimmunol. Neuroinflamm. 2020 May 15; 7: e761
- Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.Arthritis Rheum. 2010 Jan; 62: 64-74https://doi.org/10.1002/art.25034
EUA Authorized Serology Test Performance. U.S. food and drug administration website. https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-authorized-serology-test-performance. Revised June 92020. Accessed June 14, 2020.
- COVID-19 and postinfection immunity: limited evidence, many remaining questions.JAMA. 2020; 323: 2245-2246https://doi.org/10.1001/jama.2020.7869
- Antibody responses to SARS-CoV-2 in patients with COVID-19.Nat Med. 2020 Apr 29; (Online ahead of print)https://doi.org/10.1038/s41591-020-0897-1
- B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.Mult. Scler. Relat. Disord. 2020 May 13; 43 (Online ahead of print)102195https://doi.org/10.1016/j.msard.2020.102195
- Italian study group on COVID-19 infection in multiple sclerosis. An Italian programme for COVID-19 infection in multiple sclerosis.Lancet Neurol. 2020 Jun; 19 (Epub 2020 Apr 30): 481-482https://doi.org/10.1016/S1474-4422(20)30147-2
- Two X-linked Agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover.Pediatr. Allergy Immunol. 2020 Apr 22; (Online ahead of print)https://doi.org/10.1111/pai.13263
- Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis.Neurology. Apr 2018; 90 (002): S36